Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

Study Type:	Interventional
Study Design:	Intervention Model: Parallel Assignment; Primary Purpose: Treatment
Condition:	HIV Infections
Interventions:	Drug: Tipranavir (with low dose ritonavir); Drug: Comparator protease inhibitor(CPI)/low dose ritonavir(r)

  Participant Flow

  Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The discrepancy with enrollment number in the protocol section is due to 16 patients not treated. (7 from TPV/r and 9 from CPI/r). These patients were not included in any analyses or results.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Tipranavir(TPV)/Low Dose Ritonavir(r)	No text entered.
Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)	No text entered.

Participant Flow:   Overall Study

	Tipranavir(TPV)/Low Dose Ritonavir(r)	Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r)
STARTED	438	428
COMPLETED	86	32
NOT COMPLETED	352	396
Adverse Event	84	41
Protocol Violation	23	16
Lost to Follow-up	5	10
Withdrawal by Subject	29	13
Other reason not defined above	211	316

  Baseline Characteristics

  Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Tipranavir(TPV)/Low Dose Ritonavir(r)	No text entered.
Comparitor Protease Inhibitor(CPI)/Low Dose Ritonavir(r)	No text entered.
Total	Total of all reporting groups

Baseline Measures

	Tipranavir(TPV)/Low Dose Ritonavir(r)	Comparitor Protease Inhibitor(CPI)/Low Dose Ritonavir(r)	Total
Overall Participants Analyzed; [Units: Participants]	435	428	863
Age [1]; [Units: Years]; Mean (Standard Deviation)	42.5 (8.4)	42.9 (8)	42.7 (8.2)
[1] 3 patients were not randomized but treated with TPV/r. They are included in the participant flow and adverse events but not in the efficacy analysis.
Gender [1]; [Units: Participants]
Female	84	64	148
Male	351	364	715
[1] 3 patients were not randomized but treated with TPV/r. They are included in the participant flow and adverse events but not in the efficacy analysis.

  Outcome Measures

  Show All Outcome Measures

1. Primary:

Treatment Response at Week 48 [ Time Frame: after 48 weeks of treatment ]

  Show Outcome Measure 1

2. Primary:

Time to Treatment Failure Through 48 Weeks of Treatment [ Time Frame: after 48 weeks of treatment ]

  Show Outcome Measure 2

3. Secondary:

Treatment Response at Week 2 [ Time Frame: week 2 ]

  Show Outcome Measure 3

4. Secondary:

Treatment Response at Week 4 [ Time Frame: week 4 ]

  Show Outcome Measure 4

5. Secondary:

Treatment Response at Week 8 [ Time Frame: week 8 ]

  Show Outcome Measure 5

6. Secondary:

Treatment Response at Week 16 [ Time Frame: week 16 ]

  Show Outcome Measure 6

7. Secondary:

Treatment Response at Week 24 [ Time Frame: Week 24 ]

  Show Outcome Measure 7

8. Secondary:

Treatment Response at Week 32 [ Time Frame: week 32 ]

  Show Outcome Measure 8

9. Secondary:

Treatment Response at Week 40 [ Time Frame: week 40 ]

  Show Outcome Measure 9

10. Secondary:

Treatment Response at Week 56 [ Time Frame: week 56 ]

  Show Outcome Measure 10

11. Secondary:

Treatment Response at Week 64 [ Time Frame: week 64 ]

  Show Outcome Measure 11

12. Secondary:

Treatment Response at Week 72 [ Time Frame: week 72 ]

  Show Outcome Measure 12

13. Secondary:

Treatment Response at Week 80 [ Time Frame: week 80 ]

  Show Outcome Measure 13

14. Secondary:

Treatment Response at Week 88 [ Time Frame: week 88 ]

  Show Outcome Measure 14

15. Secondary:

Treatment Response at Week 96 [ Time Frame: after 96 weeks of treatment ]

  Show Outcome Measure 15

16. Secondary:

Time to Treatment Failure Through 96 Weeks of Treatment [ Time Frame: after 96 weeks of treatment ]

  Show Outcome Measure 16

17. Secondary:

Time to Confirmed Virologic Failure Through 48 Weeks of Treatment [ Time Frame: after 48 weeks of treatment ]

  Show Outcome Measure 17

18. Secondary:

Time to Confirmed Virologic Failure Through 96 Weeks of Treatment [ Time Frame: after 96 weeks of treatment ]

  Show Outcome Measure 18

19. Secondary:

Virologic Response [ Time Frame: Week 2 through Week 96 (at any point during trial) ]

  Show Outcome Measure 19

20. Secondary:

Virologic Response at Week 2 [ Time Frame: Week 2 ]

  Show Outcome Measure 20

21. Secondary:

Virologic Response at Week 4 [ Time Frame: week 4 ]

  Show Outcome Measure 21

22. Secondary:

Virologic Response at Week 8 [ Time Frame: week 8 ]

  Show Outcome Measure 22

23. Secondary:

Virologic Response at Week 16 [ Time Frame: week 16 ]

  Show Outcome Measure 23

24. Secondary:

Virologic Response at Week 24 [ Time Frame: week 24 ]

  Show Outcome Measure 24

25. Secondary:

Virologic Response at Week 32 [ Time Frame: week 32 ]

  Show Outcome Measure 25

26. Secondary:

Virologic Response at Week 40 [ Time Frame: week 40 ]

  Show Outcome Measure 26

27. Secondary:

Virologic Response at Week 48 [ Time Frame: week 48 ]

  Show Outcome Measure 27

28. Secondary:

Virologic Response at Week 56 [ Time Frame: week 56 ]

  Show Outcome Measure 28

29. Secondary:

Virologic Response at Week 64 [ Time Frame: week 64 ]

  Show Outcome Measure 29

30. Secondary:

Virologic Response at Week 72 [ Time Frame: Week 72 ]

  Show Outcome Measure 30

31. Secondary:

Virologic Response at Week 80 [ Time Frame: Week 80 ]

  Show Outcome Measure 31

32. Secondary:

Virologic Response at Week 88 [ Time Frame: Week 88 ]

  Show Outcome Measure 32

33. Secondary:

Virologic Response at Week 96 [ Time Frame: Week 96 ]

  Show Outcome Measure 33

34. Secondary:

Median Change From Baseline in Viral Load (Week 2) [ Time Frame: Baseline to Week 2 ]

  Show Outcome Measure 34

35. Secondary:

Median Change From Baseline in Viral Load (Week 4) [ Time Frame: Baseline to Week 4 ]

  Show Outcome Measure 35

36. Secondary:

Median Change From Baseline in Viral Load (Week 8) [ Time Frame: Baseline to Week 8 ]

  Show Outcome Measure 36

37. Secondary:

Median Change From Baseline in Viral Load (Week 16) [ Time Frame: Baseline to Week 16 ]

  Show Outcome Measure 37

38. Secondary:

Median Change From Baseline in Viral Load (Week 24) [ Time Frame: Baseline to Week 24 ]

  Show Outcome Measure 38

39. Secondary:

Median Change From Baseline in Viral Load (Week 32) [ Time Frame: Baseline to Week 32 ]

  Show Outcome Measure 39

40. Secondary:

Median Change From Baseline in Viral Load (Week 40) [ Time Frame: Baseline to Week 40 ]

  Show Outcome Measure 40

41. Secondary:

Median Change From Baseline in Viral Load (Week 48) [ Time Frame: Baseline to Week 48 ]

  Show Outcome Measure 41

42. Secondary:

Median Change From Baseline in Viral Load (Week 56) [ Time Frame: Baseline to Week 56 ]

  Show Outcome Measure 42

43. Secondary:

Median Change From Baseline in Viral Load (Week 64) [ Time Frame: Baseline to Week 64 ]

  Show Outcome Measure 43

44. Secondary:

Median Change From Baseline in Viral Load (Week 72) [ Time Frame: Baseline to Week 72 ]

  Show Outcome Measure 44

45. Secondary:

Median Change From Baseline in Viral Load (Week 80) [ Time Frame: Baseline to Week 80 ]

  Show Outcome Measure 45

46. Secondary:

Median Change From Baseline in Viral Load (Week 88) [ Time Frame: Baseline to Week 88 ]

  Show Outcome Measure 46

47. Secondary:

Median Change From Baseline in Viral Load (Week 96) [ Time Frame: Baseline to Week 96 ]

  Show Outcome Measure 47

48. Secondary:

Virologic Response at Week 40 [ Time Frame: Week 40 ]

  Show Outcome Measure 48

49. Secondary:

Virologic Response at Viral Load Nadir During Study Treatment Through 96 Weeks [ Time Frame: Week 2 through Week 96 (at any point during trial) ]

  Show Outcome Measure 49

50. Secondary:

Virologic Response at Week 2 [ Time Frame: Week 2 ]

  Show Outcome Measure 50

51. Secondary:

Virologic Response at Week 4 [ Time Frame: Week 4 ]

  Show Outcome Measure 51

52. Secondary:

Virologic Response at Week 8 [ Time Frame: Week 8 ]

  Show Outcome Measure 52

53. Secondary:

Virologic Response at Week 16 [ Time Frame: Week 16 ]

  Show Outcome Measure 53

54. Secondary:

Virologic Response at Week 24 [ Time Frame: Week 24 ]

  Show Outcome Measure 54

55. Secondary:

Virologic Response at Week 32 [ Time Frame: Week 32 ]

  Show Outcome Measure 55

56. Secondary:

Virologic Response at Week 48 [ Time Frame: Week 48 ]

  Show Outcome Measure 56

57. Secondary:

Virologic Response at Week 56 [ Time Frame: Week 56 ]

  Show Outcome Measure 57

58. Secondary:

Virologic Response at Week 64 [ Time Frame: Week 64 ]

  Show Outcome Measure 58

59. Secondary:

Virologic Response at Week 72 [ Time Frame: Week 72 ]

  Show Outcome Measure 59

60. Secondary:

Virologic Response at Week 80 [ Time Frame: Week 80 ]

  Show Outcome Measure 60

61. Secondary:

Virologic Response at Week 88 [ Time Frame: week 88 ]

  Show Outcome Measure 61

62. Secondary:

Virologic Response at Week 96 [ Time Frame: week 96 ]

  Show Outcome Measure 62

63. Secondary:

Virologic Response [ Time Frame: Week 2 through Week 96 (at any point during trial) ]

  Show Outcome Measure 63

64. Secondary:

Virologic Response at Week 2 [ Time Frame: Week 2 ]

  Show Outcome Measure 64

65. Secondary:

Virologic Response at Week 4 [ Time Frame: Week 4 ]

  Show Outcome Measure 65

66. Secondary:

Virologic Response at Week 8 [ Time Frame: Week 8 ]

  Show Outcome Measure 66

67. Secondary:

Virologic Response at Week 16 [ Time Frame: Week 16 ]

  Show Outcome Measure 67

68. Secondary:

Virologic Response at Week 24 [ Time Frame: Week 24 ]

  Show Outcome Measure 68

69. Secondary:

Virologic Response at Week 32 [ Time Frame: Week 32 ]

  Show Outcome Measure 69

70. Secondary:

Virologic Response at Week 40 [ Time Frame: Week 40 ]

  Show Outcome Measure 70

71. Secondary:

Virologic Response at Week 48 [ Time Frame: Week 48 ]

  Show Outcome Measure 71

72. Secondary:

Virologic Response at Week 56 [ Time Frame: Week 56 ]

  Show Outcome Measure 72

73. Secondary:

Virologic Response at Week 64 [ Time Frame: Week 64 ]

  Show Outcome Measure 73

74. Secondary:

Virologic Response at Week 72 [ Time Frame: Week 72 ]

  Show Outcome Measure 74

75. Secondary:

Virologic Response at Week 80 [ Time Frame: Week 80 ]

  Show Outcome Measure 75

76. Secondary:

Virologic Response at Week 88 [ Time Frame: Week 88 ]

  Show Outcome Measure 76

77. Secondary:

Virologic Response at Week 96 [ Time Frame: Week 96 ]

  Show Outcome Measure 77

78. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 2) [ Time Frame: Baseline to Week 2 ]

  Show Outcome Measure 78

79. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 4) [ Time Frame: Baseline to Week 4 ]

  Show Outcome Measure 79

80. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 8) [ Time Frame: Baseline to Week 8 ]

  Show Outcome Measure 80

81. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 16) [ Time Frame: Baseline to Week 16 ]

  Show Outcome Measure 81

82. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 24) [ Time Frame: Baseline to Week 24 ]

  Show Outcome Measure 82

83. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 32) [ Time Frame: Baseline to Week 32 ]

  Show Outcome Measure 83

84. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 40) [ Time Frame: Baseline to Week 40 ]

  Show Outcome Measure 84

85. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 48) [ Time Frame: Baseline to Week 48 ]

  Show Outcome Measure 85

86. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 56) [ Time Frame: Baseline to Week 56 ]

  Show Outcome Measure 86

87. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 64) [ Time Frame: Baseline to Week 64 ]

  Show Outcome Measure 87

88. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 72) [ Time Frame: Baseline to Week 72 ]

  Show Outcome Measure 88

89. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 80) [ Time Frame: Baseline to Week 80 ]

  Show Outcome Measure 89

90. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 88) [ Time Frame: Baseline to Week 88 ]

  Show Outcome Measure 90

91. Secondary:

Mean Change From Baseline in CD4+ Cell Count (Week 96) [ Time Frame: Baseline to Week 96 ]

  Show Outcome Measure 91

92. Secondary:

Time to New Centers for Disease Control (CDC) Class C Progression Event or Death. [ Time Frame: up to 75 weeks of treatment ]

  Show Outcome Measure 92

  Serious Adverse Events

  Show Serious Adverse Events

  Other Adverse Events

  Show Other Adverse Events

  Limitations and Caveats

  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

  Hide More Information

Certain Agreements:  

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is: The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo. The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo. Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.; Restriction Description: Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.

Results Point of Contact:  

Name/Title: Boehringer Ingelheim Call Center
Organization: Boehringer Ingelheim Pharmaceuticals
phone: 1-800-243-0127
e-mail: clintriage.rdg@boehringer-ingelheim.com

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mikl J, Sulkowski MS, Benhamou Y, Dieterich D, Pol S, Rockstroh J, Robinson PA, Ranga M, Stern JO. Hepatic profile analyses of tipranavir in Phase II and III clinical trials. BMC Infect Dis. 2009 Dec 14;9:203. doi: 10.1186/1471-2334-9-203.

Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H; RESIST investigator group. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006 Aug 5;368(9534):466-75.

Responsible Party:	Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier:	NCT00144170 History of Changes
Other Study ID Numbers:	1182.48; RESIST 2
First Submitted:	September 2, 2005
First Posted:	September 5, 2005
Results First Submitted:	September 11, 2009
Results First Posted:	December 23, 2009
Last Update Posted:	July 2, 2014